4,613 results match your criteria liver stiffness

Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.

Biomed Pharmacother 2022 Jan 12;147:112623. Epub 2022 Jan 12.

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis.

Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Read More

View Article and Full-Text PDF
January 2022

Diagnostic Performance of Spin-Echo Echo-Planar Imaging Magnetic Resonance Elastography in 3T System for Noninvasive Assessment of Hepatic Fibrosis.

Korean J Radiol 2022 Jan 4. Epub 2022 Jan 4.

Department of Pathology, Seoul National University Hospital, Seoul, Korea.

Objective: To validate the performance of 3T spin-echo echo-planar imaging (SE-EPI) magnetic resonance elastography (MRE) for staging hepatic fibrosis in a large population, using surgical specimens as the reference standard.

Materials And Methods: This retrospective study initially included 310 adults (155 undergoing hepatic resection and 155 undergoing donor hepatectomy) with histopathologic results from surgical liver specimens. They underwent 3T SE-EPI MRE ≤ 3 months prior to surgery. Read More

View Article and Full-Text PDF
January 2022

Derivation of "Egyptian varices prediction (EVP) index": A novel noninvasive index for diagnosing esophageal varices in HCV Patients.

J Adv Res 2022 Jan 24;35:87-97. Epub 2021 Feb 24.

Systems and Information Department, Engineering Research Division, National Research Centre, Giza, Egypt.

Introduction: Esophageal Varices (EVs) is one of the major dangerous complications of liver fibrosis. Upper Gastrointestinal (UGI) Endoscopy is necessary for its diagnosis. Repeated examinations for EVs screening severely burden endoscopic units in terms of cost and other side implications; moreover, the lack of public health resources in rural areas and primary hospitals should be considered, particularly in developing countries. Read More

View Article and Full-Text PDF
January 2022

Review of Medical Management of Primary Biliary Cholangitis.

S D Med 2021 Dec;74(12):562-568

Transplant Hepatology Program, University of Nebraska Medical Center, Omaha, Nebraska.

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with presumed autoimmune etiology. Current treatment options include ursodeoxycholic acid, obeticholic acid, and fibrate, which target mainly cholestasis. There is no effective therapy against autoimmune or hepatic fibrosis components. Read More

View Article and Full-Text PDF
December 2021

Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial.

Diabetes Obes Metab 2022 Jan 10. Epub 2022 Jan 10.

University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, TX.

Aim: To compare the efficacy of Triple Therapy (metformin/exenatide/pioglitazone) versus stepwise Conventional Therapy (metformin →glipizide →glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug naïve T2DM patients.

Research Design And Methods: 68 patients completed the 6-year follow up and had end-of-study (EOS) FibroScan to provide measures of steatosis (CAP in dB/m) and fibrosis (Liver Stiffness Measurement in kPa); 59 had MRI-PDFF to measure liver fat. At EOS, HbA1c was 6. Read More

View Article and Full-Text PDF
January 2022

Cryogel-Integrated Biochip for Liver Tissue Engineering.

ACS Appl Bio Mater 2021 Jul 8;4(7):5617-5626. Epub 2021 Jul 8.

Université de Technologie de Compiègne, UMR CNRS 7338 Biomécanique et Bioingénierie, Centre de Recherche de Royallieu, Compiègne 60203, France.

Microfluidic systems and polymer hydrogels have been widely developed for tissue engineering. Yet, only a few tools combining both approaches, especially for liver models, are being explored. In this study, an alginate-based cryogel-integrated biochip was engineered for dynamic hepatoma cell line culture in three dimensions (3D). Read More

View Article and Full-Text PDF

A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.

Aliment Pharmacol Ther 2022 Jan 9. Epub 2022 Jan 9.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.

Background And Aims: Vibration-controlled transient elastography (VCTE) has shown good diagnostic performance in predicting fibrosis stages in patients with non-alcoholic fatty liver disease (NAFLD). However, an optimal diagnostic approach to detect advanced fibrosis in patients with NAFLD has not been established.

Approach And Results: We prospectively collected data from 539 subjects who underwent liver biopsy at a single centre between January 2014 and December 2019. Read More

View Article and Full-Text PDF
January 2022

Morphologic Alterations Precede Functional Hepatic Impairment as Determined by C-Methacetin Liver Function Breath Test in Adult Fontan Patients.

Front Cardiovasc Med 2021 23;8:764009. Epub 2021 Dec 23.

Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.

Fontan-associated liver disease (FALD) is the most common end-organ dysfunction affecting up to 70-80% of the Fontan population. The clinical significance of FALD is incompletely understood and no unambiguous correlation between hepatic function and FALD severity has been established. In this study, we sought to evaluate maximal liver function capacity with liver maximum function capacity test (LiMAx®) in adult Fontan patients. Read More

View Article and Full-Text PDF
December 2021

Association Between Infection and Non-alcoholic Fatty Liver Disease, Hepatic Adipose Deposition and Stiffness in Southwest China.

Front Med (Lausanne) 2021 24;8:764472. Epub 2021 Dec 24.

Health Management Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Both nonalcoholic fatty liver disease (NAFLD) and () infection have high prevalence worldwide, and the relationship between both remains controversial. We try to investigate whether infection is associated with NAFLD and increased liver fat deposition and stiffness in this cross-sectional study. The physical examination data of 5,665 subjects were obtained from February 2018 to June 2019 in this study. Read More

View Article and Full-Text PDF
December 2021

Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4.

J Clin Gastroenterol 2022 Jan 10. Epub 2022 Jan 10.

Division of Gastroenterology, Hepatology, and Nutrition Department of Biostatistics Division of Interventional Radiology, Virginia Commonwealth University Division of Gastroenterology and Hepatology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, VA Section of Digestive Diseases, Yale University, New Haven, CT.

Background: Liver biopsy and hepatic venous pressure gradient (HVPG), the gold standard for assessing advanced fibrosis (AF) and clinically significant portal hypertension (CSPH), are invasive, costly, and time-consuming.

Goal: We investigated if the combination of fibrosis index based on 4 factors (FIB-4) and liver stiffness measure (LSM) can identify AF and more importantly, CSPH.

Patients And Methods: Patients with chronic liver disease referred for transjugular liver biopsy were analyzed retrospectively. Read More

View Article and Full-Text PDF
January 2022

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.

Sci Rep 2022 Jan 7;12(1):193. Epub 2022 Jan 7.

Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Read More

View Article and Full-Text PDF
January 2022

Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis.

Hepatol Commun 2022 Jan 6. Epub 2022 Jan 6.

Liver Unit, Hospital Clínic Barcelona, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain.

The value of noninvasive tools in the diagnosis of autoimmune hepatitis (AIH)-related cirrhosis and the prediction of clinical outcomes is largely unknown. We sought to evaluate (1) the utility of liver stiffness measurement (LSM) in the diagnosis of cirrhosis and (2) the performance of the Sixth Baveno Consensus on Portal Hypertension (Baveno VI), expanded Baveno VI, and the ANTICIPATE models in predicting the absence of varices needing treatment (VNT). A multicenter cohort of 132 patients with AIH-related cirrhosis was retrospectively analyzed. Read More

View Article and Full-Text PDF
January 2022

Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.

Aliment Pharmacol Ther 2022 Jan 5. Epub 2022 Jan 5.

Palermo, Italy.

Background & Aim: Non-alcoholic fatty liver disease (NAFLD), and especially fibrotic non-alcoholic steatohepatitis, is associated with high risks of liver-related events (LRE) and extrahepatic events (EHE). We evaluated the competitive risk occurrence of LRE and EHE in a large cohort of biopsy-proven NAFLD stratified according to baseline severity of fibrosis.

Methods: Two thousand one hundred thirty-five patients with biopsy-proven NAFLD were enrolled. Read More

View Article and Full-Text PDF
January 2022

Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States.

Obes Surg 2022 Jan 5. Epub 2022 Jan 5.

Department of Medicine and Rehabilitation, Policlinico Di Monza, 20900, Monza, Italy.

Purpose: Obesity represents a well-known risk factor for metabolic-dysfunction associated fatty liver disease (MAFLD) and its progression towards cirrhosis. The aim of this study is to estimate the proportion of potential candidates to a bariatric surgery intervention that has an elevated liver stiffness on vibration-controlled transient elastography (VCTE).

Materials And Methods: This is a cross-sectional study performed using data obtained during the 2017-2018 cycle of the National Health and Nutrition Examination Survey. Read More

View Article and Full-Text PDF
January 2022

The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection.

Biomed Rep 2022 Feb 7;16(2). Epub 2021 Dec 7.

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

Single-nucleotide polymorphisms (SNPs) of patatin-like phospholipase domain-containing 3 (), tolloid-like protein 1 () and interleukin-28 () have been identified as susceptibility factors for liver steatosis, inflammation and fibrosis in patients with hepatitis C virus (HCV) infection. Here, whether these polymorphisms affected predispositions to changes in liver stiffness (LS) and controlled attenuation parameter (CAP) following direct-acting antiviral (DAA) therapy was assessed. The changes in LS and steatosis in 77 HCV-infected patients receiving DAA therapy were compared with , and genotypes, using CAP, FibroScan and Virtual Touch tissue quantification (VTTQ) before treatment and 12 weeks after the end of the treatment. Read More

View Article and Full-Text PDF
February 2022

The association between serum albumin and depression in chronic liver disease may differ by liver histology.

BMC Psychiatry 2022 Jan 4;22(1). Epub 2022 Jan 4.

Department of Rehabilitation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, China.

Background: There are conflicting results regarding the association between chronic liver disease (CLD) and depression and the underlying biological mechanisms are lack of investigation. To address the impact of depression and its effects on the management of CLD, its biological marker is critical to be identified. The present study explored the association between serum albumin and depression in CLD patients and whether the association varied in different liver histological stages. Read More

View Article and Full-Text PDF
January 2022

Intra-patient comparison of 3D and 2D magnetic resonance elastography techniques for assessment of liver stiffness.

Abdom Radiol (NY) 2022 Jan 4. Epub 2022 Jan 4.

Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N. Saint Clair Street, Suite 800, Chicago, IL, 60611, USA.

Purpose: To evaluate performance of 3D magnetic resonance elastography (MRE) using spin-echo echo-planar imaging (seEPI) for assessment of hepatic stiffness compared with 2D gradient-recalled echo (GRE) and 2D seEPI sequences.

Methods: Fifty-seven liver MRE examinations including 2D GRE, 2D seEPI, and 3D seEPI sequences were retrospectively evaluated. Elastograms were analyzed by 2 radiologists and polygonal regions of interests (ROIs) were drawn in 2 different fashions: "curated" ROI (avoiding liver edge, major vessels, and areas of wave interferences) and "non-curated" ROI (including largest cross section of liver, to assess the contribution of artifacts). Read More

View Article and Full-Text PDF
January 2022

Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods.

Aliment Pharmacol Ther 2022 Jan 3. Epub 2022 Jan 3.

Hepatology Unit, Hôpital Haut Lévêque, Bordeaux University Hospital, Bordeaux, France.

Background: Non-invasive assessment of fibrosis is predictive of the prognosis of non-alcoholic and alcoholic fatty liver disease but this has not been demonstrated in metabolic (dysfunction)-associated fatty liver disease (MAFLD).

Aims: We assessed the prognosis of non-invasive methods in patients with MAFLD.

Methods: All consecutive patients with MAFLD, with liver stiffness measurements, FIB-4 (Fibrosis-4), and LIVERFASt were included in this cohort study. Read More

View Article and Full-Text PDF
January 2022

Non-invasive tools for detection of liver disease in children and adolescents with cystic fibrosis.

Transl Pediatr 2021 Nov;10(11):2952-2959

Institute of Biostructure and Bioimaging IBB, CNR, Naples, Italy.

Background: Cystic fibrosis (CF) is a multi-organ genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes the CFTR protein. CF-associated liver disease (CFLD) is a common complication; diagnosis is based on clinical, laboratory findings and abdominal imaging. However, non-invasive diagnostic approaches are needed to early detect CFLD, its progression and severity. Read More

View Article and Full-Text PDF
November 2021

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.

Clin Gastroenterol Hepatol 2021 Dec 29. Epub 2021 Dec 29.

Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Department for Clinical Research, University of Southern Denmark, Odense, Denmark.

Background & Aims: Fibrosis-4 (FIB-4) and the nonalcoholic fatty liver disease fibrosis score (NFS) are the 2 most popular noninvasive blood-based serum tests proposed for widespread fibrosis screening. We therefore aimed to describe the accuracy of FIB-4 and NFS to detect elevated liver stiffness as an indicator of hepatic fibrosis in low-prevalence populations.

Methods: This study included a total of 5129 patients with concomitant measurement of FIB-4, NFS, and liver stiffness measurement (LSM) by Fibroscan (Echosens, France) from 5 independent population-based cohorts from Spain, Hong Kong, Denmark, England, and France; 3979 participants from the general population and 1150 from at-risk cohorts due to alcohol, diabetes, or obesity. Read More

View Article and Full-Text PDF
December 2021


Eur J Prev Cardiol 2021 Dec 31. Epub 2021 Dec 31.

Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, the Netherlands.

Background: Lomitapide is a lipid-lowering agent indicated as adjunct therapy for adult HoFH.

Objectives: This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe.

Methods: In a multicenter retrospective, observational study including 75 HoFH patients treated with lomitapide in a real-world clinical setting from 9 European countries, LDL-C changes, adverse events (AEs) as well as major adverse cardiovascular events (MACE) were assessed. Read More

View Article and Full-Text PDF
December 2021

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.

Cancer Med 2021 Dec 30. Epub 2021 Dec 30.

IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.

In adult patients, acute lymphoblastic leukemia (ALL) is a rare hematological cancer with a cure rate below 50% and frequent relapses. With traditional therapies, patients with relapsed or refractory (R/R) ALL have a survival that may be measured in months; in these patients, inotuzumab ozogamicin (IO) is an effective therapy. IO was linked to increased risk of veno-occlusive disease/sinusoid obstruction syndrome (VOD/SOS), liver injury, and various grade of liver-related complications during clinical trials and real-life settings; however, hepatologic monitoring protocol is not established in this population. Read More

View Article and Full-Text PDF
December 2021

The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients.

Transplant Direct 2022 Jan 23;8(1):e1272. Epub 2021 Dec 23.

Liver Transplant Unit, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona, Barcelona, Spain.

Background: Long-term cardiovascular (CV) events are a frequent cause of death and disability after liver transplant (LT). Although a more in-depth, risk-adapted control of CV risk factors may result in improved post-LT CV outcomes, an accurate stratification of the CV risk of LT recipients to better implement preventive strategies is lacking. Aortic pulse wave velocity (aPWV) is a surrogate of arterial stiffness that has been suggested as a biomarker of CV risk; it has never been evaluated in adult LT recipients. Read More

View Article and Full-Text PDF
January 2022

Prevalence of Hepatic Steatosis and Fibrosis in the United States.

Metab Syndr Relat Disord 2021 Dec 27. Epub 2021 Dec 27.

Hepatology/Gastroenterology Service, Department of Medicine, Womack Army Medical Center, Fort Bragg, North Carolina, USA.

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. We evaluated vibration-controlled transient elastography (VCTE) data to determine the prevalence of two principle manifestations of NAFLD, hepatic steatosis and hepatic fibrosis. Data were sourced from the 2017 to 2018 National Health and Nutrition Examination Survey, which provides a representative cross-section of the noninstitutionalized U. Read More

View Article and Full-Text PDF
December 2021

Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.

Clin Gastroenterol Hepatol 2021 Dec 25. Epub 2021 Dec 25.

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

Background & Aims: The population prevalence of high-risk non-alcoholic steatohepatitis (NASH), defined as nonalcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2, is unknown. The FibroScan-AST (FAST) score, calculated using liver stiffness measurement and controlled attenuation parameter values from FibroScan and aspartate aminotransferase levels, is a validated algorithm to identify individuals with high-risk NASH. We estimated the prevalence of high-risk NASH using the FAST score in the United States population. Read More

View Article and Full-Text PDF
December 2021

Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.

Isr Med Assoc J 2021 Dec;23(12):794-800

Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Israel.

Background: New direct acting antiviral agent (DAA) therapies are associated with a high sustained virological response rate (SVR) in hepatitis C virus (HCV) patients. The understanding of the impact of SVR on fibrosis stage is limited.

Objectives: To determine the effect of treatment with the DAAs on long-term liver fibrosis stages, as determined by shear-wave elastography (SWE) or FibroTest. Read More

View Article and Full-Text PDF
December 2021

The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.

J Magn Reson Imaging 2021 Dec 25. Epub 2021 Dec 25.

Department of Surgical Sciences, Section of Radiology, Uppsala University, Uppsala, Sweden.

Background: Nonalcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide. It is subdivided into nonalcoholic fatty liver (NAFL) and the more aggressive form, nonalcoholic steatohepatitis (NASH), which carries a higher risk of developing fibrosis and cirrhosis. There is currently no reliable non-invasive method for differentiating NASH from NAFL. Read More

View Article and Full-Text PDF
December 2021

Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.

Liver Int 2021 Dec 25. Epub 2021 Dec 25.

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Background & Aims: The applicability of the novel metabolic dysfunction associated fatty liver disease (MAFLD) definition has been studied in numerous cohorts and compared to non-alcoholic fatty liver disease (NAFLD). No consensus has been reached on which definition is preferred. Therefore, this meta-analysis aims to compare the epidemiological and clinical features of NAFLD and MAFLD in the general and non-general population. Read More

View Article and Full-Text PDF
December 2021

Insights from the 4C-T Study suggest increased cardiovascular burden in girls with end stage kidney disease before and after kidney transplantation.

Kidney Int 2021 Dec 21. Epub 2021 Dec 21.

Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany. Electronic address:

Mortality in children with kidney failure is higher in girls than boys with cardiovascular complications representing the most common causes of death. Pulse wave velocity (PWV), a measure of vascular stiffness, predicts cardiovascular mortality in adults. Here, PWV in children with kidney failure undergoing kidney replacement therapy was investigated to determine sex differences and potential contributing factors. Read More

View Article and Full-Text PDF
December 2021

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.

Hepatology 2021 Dec 24. Epub 2021 Dec 24.

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Background & Aims: While hepatic fibrosis often affects the liver globally, the spatial distribution can be heterogeneous. This study aimed to investigate the effect of liver stiffness heterogeneity on concordance between MR elastography (MRE)-based fibrosis staging and biopsy staging in patients with nonalcoholic fatty liver disease (NAFLD).

Approach & Results: We retrospectively evaluated data from 155 NAFLD patients who underwent liver biopsy and 3T MRE and undertook a retrospective validation study of 169 NAFLD patients at three hepatology centers. Read More

View Article and Full-Text PDF
December 2021